×
About 500 results

ALLMedicine™ Fibrodysplasia Ossificans Progressiva Center

Research & Reviews  190 results

Twists in the fibrodysplasia ossificans progressiva story challenge and expand our unde...
https://doi.org/10.1172/JCI160773
The Journal of Clinical Investigation; Collins MT

Jun 16th, 2022 - Fibrodysplasia ossificans progressiva (FOP) is an ultrarare, debilitating disease in which heterotopic bone is formed in certain soft tissues. A gain-of-function variant in the cytoplasmic domain of the activin A receptor type I (ACVR1) exists in ...

The Examination of Safety and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
https://clinicaltrials.gov/ct2/show/NCT05394116

May 27th, 2022 - The study population consists of patients with Fibrodysplasia ossificans progressiva (FOP). Key primary objectives are: To assess the effect of high dose garetosmab versus placebo on the formation of new heterotopic ossification (HO) lesions from ...

Fibrodysplasia Ossificans Progressiva
https://emedicine.medscape.com/article/1112501-overview

May 13th, 2022 - Practice Essentials Fibrodysplasia ossificans progressiva (FOP) is a rare, severely disabling, autosomal dominant disease characterized by recurrent painful episodes of soft-tissue swelling and the development of tumors in subcutis and muscle tiss...

Fibrodysplasia Ossificans Progressiva
https://emedicine.medscape.com/article/1112501-print

May 13th, 2022 - Practice Essentials Fibrodysplasia ossificans progressiva (FOP) is a rare, severely disabling, autosomal dominant disease characterized by recurrent painful episodes of soft-tissue swelling and the development of tumors in subcutis and muscle tiss...

see more →

Clinicaltrials.gov  7 results

The Examination of Safety and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
https://clinicaltrials.gov/ct2/show/NCT05394116

May 27th, 2022 - The study population consists of patients with Fibrodysplasia ossificans progressiva (FOP). Key primary objectives are: To assess the effect of high dose garetosmab versus placebo on the formation of new heterotopic ossification (HO) lesions from ...

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
https://clinicaltrials.gov/ct2/show/NCT03312634

Mar 15th, 2022 - One primary objective is to evaluate the efficacy of palovarotene in decreasing new HO in subjects with FOP as assessed by low-dose, whole body computed tomography (WBCT), excluding head, compared to untreated subjects from Clementia's FOP natural...

An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in People With Fibrodysplasia Ossificans Progressiva (FOP) in France
https://clinicaltrials.gov/ct2/show/NCT02979769

Feb 17th, 2022 - The main objective of this Phase 2, open-label study is to evaluate the safety and efficacy of different palovarotene dosing regimens in participants with FOP in France. Efficacy will be assessed based on the ability of palovarotene to prevent the...

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
https://clinicaltrials.gov/ct2/show/NCT02279095

Feb 17th, 2022 - The main objective of this Phase 2, multicenter, open-label study is to evaluate the safety and efficacy of different palovarotene dosing regimens in participants with FOP. Efficacy will be assessed based on the ability of palovarotene to prevent ...

Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)
https://clinicaltrials.gov/ct2/show/NCT04577820

Nov 1st, 2021 - The primary safety objective of the study is to assess the safety and tolerability of garetosmab in Japanese male and female adult patients with FOP. The primary efficacy objective of the study is to assess the effect of garetosmab on Heterotopic ...

see more →

News  3 results

Erythematous Nodule With Central Erosions on the Calf
https://www.mdedge.com/dermatology/article/248794/dermatopathology/erythematous-nodule-central-erosions-calf
Paul J. Shim, BS, David Terrano, MD et. al.

Nov 16th, 2021 - The Diagnosis: Osteoma Cutis Osteoma cutis is the heterotopic development of cutaneous ossifications in the dermis or subcutaneous fat and presents as plaquelike, stony, hard nodules. It can manifest as either a primary or secondary condition base.

Hair Follicle Bulb Region: A Potential Nidus for the Formation of Osteoma Cutis
https://www.mdedge.com/dermatology/article/235477/dermatopathology/hair-follicle-bulb-region-potential-nidus-formation
Arif Suhail Usmani, MD

Feb 3rd, 2021 - The term osteoma cutis (OC) is defined as the ossification or bone formation either in the dermis or hypodermis. 1 It is heterotopic in nature, referring to extraneous bone formation in soft tissue.

BRIEF-Ipsen Shares Eight Abstracts On Rare Diseases
https://www.reuters.com/article/brief-ipsen-shares-eight-abstracts-on-ra/brief-ipsen-shares-eight-abstracts-on-rare-diseases-idUSFWN2DI0SM

Jun 8th, 2020 - June 8 (Reuters) - IPSEN SA: * IPSEN DEMONSTRATES CONTINUED COMMITMENT TO RARE DISEASES WITH EIGHT ABSTRACTS ACCEPTED AT ENDO 2020 PUBLISHED IN JOURNAL OF ENDOCRINE SOCIETY * DATA PUBLISHED EVALUATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) NAT...

see more →